134 related articles for article (PubMed ID: 16619511)
1. Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy.
Hambek M; Werner C; Baghi M; Gstöttner W; Knecht R
Anticancer Res; 2006; 26(2A):1091-5. PubMed ID: 16619511
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation.
Hambek M; Werner C; Baghi M; Gstöttner W; Knecht R
Eur J Cancer; 2007 Jul; 43(10):1502-7. PubMed ID: 17524637
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells.
Rossi MJ; Sundararaj K; Koybasi S; Phillips MS; Szulc ZM; Bielawska A; Day TA; Obeid LM; Hannun YA; Ogretmen B
Otolaryngol Head Neck Surg; 2005 Jan; 132(1):55-62. PubMed ID: 15632910
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
7. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
9. Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor.
Kavanagh BD; Lin PS; Chen P; Schmidt-Ullrich RK
Clin Cancer Res; 1995 Dec; 1(12):1557-62. PubMed ID: 9815956
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio.
Marcu LG; Bezak E
J Theor Biol; 2012 Mar; 297():41-7. PubMed ID: 22182756
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo.
Gutschalk CM; Herold-Mende CC; Fusenig NE; Mueller MM
Cancer Res; 2006 Aug; 66(16):8026-36. PubMed ID: 16912178
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.
Czembirek C; Eder-Czembirek C; Erovic BM; Turhani D; Selzer E; Thurnher D
Oncol Rep; 2005 Dec; 14(6):1523-6. PubMed ID: 16273249
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation.
Laderoute KR; Ausserer WA; Knapp AM; Grant TD; Sutherland RM
Cancer Res; 1994 Mar; 54(6):1407-11. PubMed ID: 8137238
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer.
Wang SJ; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2006 Jul; 132(7):771-8. PubMed ID: 16847188
[TBL] [Abstract][Full Text] [Related]
16. [Cisplatin-induced apoptosis in laryngeal squamous cell carcinoma strain and the influence on cell cycle].
Qi F; Zhang B; Xu Y
Zhonghua Yi Xue Za Zhi; 1999 Apr; 79(4):298-301. PubMed ID: 11601059
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.
Light BW; Yu WD; McElwain MC; Russell DM; Trump DL; Johnson CS
Cancer Res; 1997 Sep; 57(17):3759-64. PubMed ID: 9288784
[TBL] [Abstract][Full Text] [Related]
18. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
19. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
Cohen EE; Lingen MW; Zhu B; Zhu H; Straza MW; Pierce C; Martin LE; Rosner MR
Cancer Res; 2006 Jun; 66(12):6296-303. PubMed ID: 16778206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
